Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
11.13
Oct 30 • 3:59 PM ET Dollar change-0.97 Percentage change(-8.02%)
Aftermarket Close
11.30
Aftermarket • 7:57 PM ET Dollar change+0.17 Percentage change(1.53%)
Index
RUT
Market Cap
1.91B
Enterprise Value
1.71B
Income
-121.08M
Sales
1.56M
Book/sh
1.43
Cash/sh
1.17
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
140
IPO
Jul 22, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
1224.40
P/B
7.76
P/C
9.50
P/FCF
-
EV/EBITDA
-
EV/Sales
1097.92
Quick Ratio
10.63
Current Ratio
10.63
Debt/Eq
0.02
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-0.80
EPS next Y
-0.73
EPS next Q
-0.19
EPS this Y
4.79%
EPS next Y
8.77%
EPS next 5Y
10.61%
EPS past 3/5Y
9.99% -9.45%
Sales past 3/5Y
-21.31% -10.14%
EPS Y/Y TTM
15.36%
Sales Y/Y TTM
-62.28%
EPS Q/Q
11.98%
Sales Q/Q
-46.37%
Insider Own
13.68%
Insider Trans
0.21%
Inst Own
83.58%
Inst Trans
19.67%
ROA
-50.57%
ROE
-57.72%
ROIC
-48.87%
Gross Margin
-610.70%
Oper. Margin
-8411.27%
Profit Margin
-7756.37%
SMA20
13.52%
SMA50
17.07%
SMA200
71.51%
Trades
Shs Outstand
171.56M
Shs Float
148.14M
52W High
12.54 -11.28%
52W Low
2.24 396.88%
Volatility
11.46% 9.75%
ATR (14)
0.95
RSI (14)
57.74
Beta
2.24
Rel Volume
1.29
Avg Volume
3.54M
Volume
4,563,836
Perf Week
21.24%
Perf Month
3.53%
Perf Quarter
40.35%
Perf Half Y
126.22%
Perf YTD
218.91%
Perf Year
172.13%
Perf 3Y
827.50%
Perf 5Y
-24.13%
Perf 10Y
-
Prev Close
12.10
Price
11.13
Change %
-8.02%
Consensus
Strong Buy
Avg. Price Target
$14.82
Implied Upside
+33.2%
Analysts16incl. previous ratings
Rating Distribution12 Buy · 3 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 29, 2026Initiated
JEF logoJJefferies
Buy$14+25.8%
Jun 04, 2026Initiated
LLeerink Partners
Outperform$12+7.8%
May 28, 2026Initiated
BBTIG Research
Buy$9-19.1%
Jan 08, 2026Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$4.32-61.2%
Oct 02, 2025Initiated
JPM logoJJP Morgan
Overweight
Jul 03, 2025Resumed
MS logoMMorgan Stanley
Overweight$7-37.1%
Jan 22, 2025Initiated
NNeedham
Buy$9-19.1%
Oct 02, 2024Initiated
GGuggenheim
Buy$10-10.2%
Jul 03, 2024Initiated
MS logoMMorgan Stanley
Overweight$7-37.1%
Mar 14, 2024Initiated
BNS logoBScotiabank
Sector Outperform$13+16.8%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Szela Mary TDirectorJun 30 '26Buy11.5412,900148,86621,300Jul 06 04:06 PM
Pangalos Menelas NDirectorMay 13 '26Buy5.3637,453200,748232,308May 13 04:05 PM
Busch AndreasChief Innovation OfficerMar 12 '26Buy2.29100,000229,000421,446Mar 16 04:17 PM
Pangalos Menelas NDirectorFeb 27 '26Buy2.7475,095205,760189,055Mar 03 04:13 PM
McClain SeanChief Executive OfficerFeb 23 '26Option Exercise1.21396,399479,6438,730,966Feb 25 06:05 PM
McClain SeanChief Executive OfficerFeb 02 '26Sale2.9926,76180,0158,334,567Feb 04 04:52 PM
Jonasson ZachariahCFO / CBOFeb 02 '26Sale2.9917,49652,313383,538Feb 04 04:51 PM
VAN HOUTEN FRANSDirectorDec 05 '25Buy3.7240,000148,80063,320Dec 09 04:04 PM
Absci Corp. engages in drug discovery with generative design to create biologics for patients. Its platform combines AI models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. The firm has its own pipeline of AI designed therapeutics including ABS-201 and ABS-202. Absci Corp was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
FounderMr. Sean McClain
Chief Business Officer & CFODr. Zachariah Jonasson Ph.D.
Senior VP & Chief Accounting OfficerMr. Todd Bedrick CPA
CVP of Finance & Head of Investor RelationsMr. Alexander Khan CPA
Chief Legal OfficerMs. Shelby Walker J.D.